Skip to content

Medicinal Chemistry Formula Sheet and Short Notes

One-page CSIR NET revision: drug targets and inhibition constants, logP and QSAR, metabolism and pharmacokinetics formulas, and drug-class targets.

  • 7 min read
  • Updated
On this page · 9 sections
  1. Binding and inhibition
  2. Properties and drug-likeness
  3. SAR, bioisosteres and QSAR
  4. Metabolism
  5. Pharmacokinetics
  6. Drug classes at a glance
  7. Exam pattern for this chapter
  8. Last-minute checklist
  9. Where to go next

Every formula, target and trap from Drug Targets and Molecular Basis of Drug Action, Physicochemical Properties, SAR and QSAR, Drug Metabolism, Prodrugs and Pharmacokinetics and Major Drug Classes and Their Chemistry, on one page.

Constants used: \( R = 8.314 \) J K⁻¹ mol⁻¹; at 298.15 K, \( RT = 2.479 \) kJ mol⁻¹ and \( RT\ln 10 = 5.71 \) kJ mol⁻¹ (= 1.37 kcal mol⁻¹) per log unit.

Binding and inhibition

$$\theta = \frac{[\mathrm{D}]}{K_d + [\mathrm{D}]}, \qquad \Delta G^\circ = RT\ln K_d, \qquad \mathrm{p}K_i = -\log K_i$$$$K_i = \frac{\mathrm{IC}_{50}}{1 + [\mathrm{S}]/K_M}\ (\text{enzyme}), \qquad K_i = \frac{\mathrm{IC}_{50}}{1 + [\mathrm{L}]/K_d}\ (\text{radioligand}), \qquad r - 1 = \frac{[\mathrm{B}]}{K_B}\ (\text{Schild})$$
  • One log unit of \( K_d \) = 5.7 kJ mol⁻¹. \( K_d = 1 \) nM → −51.4 kJ mol⁻¹; 10 nM → −45.7 kJ mol⁻¹.
  • At \( [\mathrm{S}] = K_M \), IC\(_{50} = 2K_i \).
  • Schild slope 1 = simple competition; p\(A_2 = -\log K_B \); \( [\mathrm{B}] = 10^{-6} \) with \( r = 21 \) gives \( K_B = 5\times10^{-8} \), p\(A_2 = 7.3 \).
  • Covalent inhibition: \( k_{\text{obs}} = k_{\text{inact}}[\mathrm{I}]/(K_I + [\mathrm{I}]) \); time-dependent, saturable, not reversed by dialysis.
Inhibition typeLineweaver–BurkApparent \( V_{\max} \) / \( K_M \)
Competitivemeet on \( 1/v \) axis\( V_{\max} \) same, \( K_M \) up
Uncompetitiveparallelboth down
Pure non-competitivemeet on \( 1/[\mathrm{S}] \) axis\( V_{\max} \) down, \( K_M \) same
Receptor termMeaning
Full / partial agonistmaximal / submaximal plateau
Inverse agonistbelow constitutive baseline
Competitive antagonistparallel right shift, \( E_{\max} \) kept
Irreversible antagonist\( E_{\max} \) depressed

Properties and drug-likeness

$$\log D = \log P - \log\!\left(1 + 10^{\Delta}\right), \qquad \Delta = \mathrm{pH} - \mathrm{p}K_a\ (\text{acid}),\ \ \mathrm{p}K_a - \mathrm{pH}\ (\text{base})$$
  • \( \pi_X = \log P_{\mathrm{RX}} - \log P_{\mathrm{RH}} \); positive for alkyl, halogen, CF\(_3\); negative for OH, NH\(_2\), CONH\(_2\).
  • Ionised fraction (acid) \( = 1/(1 + 10^{\mathrm{p}K_a - \mathrm{pH}}) \). Acid \( \mathrm{p}K_a \) 4.4 at pH 7.4: 99.9% ionised, \( \log D = \log P - 3.0 \).
  • Only the neutral species crosses a membrane passively (pH–partition).
  • Lipinski: mass ≤ 500, \( \log P \) ≤ 5, H-bond donors ≤ 5, acceptors ≤ 10 (≥2 violations = likely poor oral absorption).
  • Veber: rotatable bonds ≤ 10, PSA ≤ 140 Å\(^2\) (lower still for CNS).
  • At pH 7.4: COOH ionised, aliphatic amine protonated, amide and pyridine neutral.

SAR, bioisosteres and QSAR

$$\log\frac{1}{C} = -k_1(\log P)^2 + k_2\log P + k_3\sigma + k_4E_s + k_5, \qquad \log P_0 = \frac{k_2}{2k_1}$$
ToolUse
Craig plotchoose substituents spanning all four \( \pi \)–\( \sigma \) quadrants (avoid colinearity)
Topliss treestepwise, non-statistical substituent choice
Free–Wilsonadditive group contributions, no physical parameters, no extrapolation
CoMFA / 3D-QSARaligned molecules, grid fields, PLS regression
BioisostereReplaces
Tetrazole, acylsulfonamideCOOH
FH (blocks metabolism, lowers amine \( pK_a \))
Pyridylphenyl (lowers \( \log P \))
1,2,4-Oxadiazole, trans-alkeneamide
$$\mathrm{LE} \approx \frac{1.37\,\mathrm{pIC}_{50}}{N_{\text{heavy atoms}}}\ \text{kcal mol}^{-1}\text{ atom}^{-1}, \qquad \mathrm{LLE} = \mathrm{pIC}_{50} - \log P$$
  • Worked anchors: pIC\(_{50}\) 8 with 25 heavy atoms → LE 0.44; pIC\(_{50}\) 6 with 15 atoms → LE 0.55.
  • \( \log(1/C) = -0.22(\log P)^2 + 1.32\log P + 1.60\sigma + 2.10 \) → \( \log P_0 = 3.00 \), best value 4.08 at \( \sigma = 0 \) (illustrative coefficients).

Metabolism

PhaseChemistry
IP450 oxidation (aliphatic and aromatic hydroxylation, N/O/S-dealkylation, N/S-oxidation, epoxidation, oxidative deamination); hydrolysis by esterases/amidases; reduction of nitro and azo groups
IIglucuronidation (UDPGA), sulfation (PAPS), glutathione conjugation (→ mercapturic acids), acetylation (acetyl-CoA), methylation (SAM), amino-acid conjugation
$$\mathrm{RH} + \mathrm{O_2} + \mathrm{NADPH} + \mathrm{H^+} \longrightarrow \mathrm{ROH} + \mathrm{H_2O} + \mathrm{NADP^+}$$
  • P450 is a haem-thiolate monooxygenase; CYP3A4 handles the largest share of drugs, CYP2D6 is notably polymorphic.
  • Inhibition raises exposure quickly; induction lowers it over days (rifampicin, carbamazepine, St John’s wort are standard inducers).
  • Bioactivation: arene oxides (NIH shift), quinone imines (paracetamol → NAPQI, captured by glutathione), acyl glucuronides, nitrenium ions.
  • Blocking strategies: aromatic F, steric shielding, amide for ester, remove the catechol.
  • Prodrug on, soft drug off. Enalapril (ester), levodopa (transporter), sulfasalazine (gut azoreductase), acyclovir (viral TK), omeprazole (acid), cyclophosphamide (hepatic oxidation), codeine (3-O-methyl).

Pharmacokinetics

$$C = C_0e^{-kt}, \quad t_{1/2} = \frac{0.693}{k}, \quad V_d = \frac{D}{C_0}, \quad \mathrm{CL} = kV_d, \quad \mathrm{AUC} = \frac{FD}{\mathrm{CL}}$$$$F = \frac{\mathrm{AUC_{oral}}/D_{\text{oral}}}{\mathrm{AUC_{iv}}/D_{\text{iv}}}, \qquad \text{loading dose} = V_dC_{\text{target}}, \qquad \text{infusion rate} = \mathrm{CL}\,C_{\text{target}}$$
  • Steady state after 4–5 half-lives, independent of dose; 90% needs 3.32 half-lives.
  • Worked anchor: \( t_{1/2} = 4.0 \) h, \( V_d = 35 \) L → \( k = 0.173 \) h⁻¹, CL = 6.07 L h⁻¹; 350 mg oral at \( F = 0.75 \) → AUC = 43.3 mg h L⁻¹.
  • Saturated (Michaelis–Menten) elimination: first order below \( K_M \), zero order above; half-life no longer constant.

Drug classes at a glance

ClassTarget
Penicillins, cephalosporinstranspeptidase (PBP); clavulanate inhibits β-lactamase
VancomycinD-Ala-D-Ala terminus (substrate, not enzyme)
Aminoglycosides, tetracyclines30S
Macrolides, chloramphenicol, oxazolidinones50S
FluoroquinolonesDNA gyrase, topoisomerase IV
Sulfonamidesdihydropteroate synthase (PABA antimetabolite)
Trimethoprim / methotrexatebacterial / human dihydrofolate reductase
5-Fluorouracil (as FdUMP)thymidylate synthase (suicide)
Acyclovir, zidovudineviral polymerase / RT — chain termination
HIV protease inhibitorsaspartyl protease (transition-state isostere)
Azoles / polyenes14α-demethylase (haem Fe) / ergosterol
Nitrogen mustards, cisplatinDNA alkylation / cross-linking
Vinca alkaloids / taxanestubulin: destabilise / stabilise
Aspirin / other NSAIDs / coxibsCOX: irreversible acetylation / reversible / COX-2 pocket
Opioidsopioid receptors; N-substituent sets agonist vs antagonist
β-Blockersβ-adrenoceptors (aryloxypropanolamine; \( S \) more active)
ACE inhibitorszinc peptidase (thiol or carboxylate zinc-binding group)
DihydropyridinesL-type Ca\(^{2+}\) channel (Hantzsch-type 1,4-DHP)
StatinsHMG-CoA reductase (intermediate mimic)
Proton-pump inhibitorsH\(^+\)/K\(^+\)-ATPase (acid-activated sulfenamide)
BenzodiazepinesGABA\(_A\) positive allosteric modulation
Local anaestheticsvoltage-gated Na\(^+\) channels

Exam pattern for this chapter

Per the NTA information bulletin for the December 2026 cycle, Chemical Sciences Part B gives 40 questions (attempt 35, +2/−0.5, maximum 70) and Part C gives 60 questions (attempt 25, +4/−1, maximum 100), in one 3-hour, 200-mark paper. Only the first permitted number of answered questions in a part is evaluated.

Last-minute checklist

Where to go next

Advertisement
Advertisement